Citations

Mayo Clinic

Showing 10 of 108585 citations.

The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions
Chambers, Henry F. , Cross, H. R. , Souli, Maria , Patel, Robin , Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Deckard, Nancie , Schuler, Carl, Bunn, Ivra, Zaharoff, Smitha, Sharma, Shrabani, Wickward, Cathy, Waller, Jason, Wilson, Holly, Baum, Keri, Komarow, Lauren , Evans, Beth , Hopkins, D. E., Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Schwager, Nyssa, Mau, Donald, Satlin, Michael J. , Schooley, Robert T. , Sund, Zoë, Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Doernberg, Sarah B. , Raza, Praneeta , Zeng, Lijuan , Banerjee, Ritu , Abbenante, Erin, Mocka, Elizabeth, King, H. A. , Kinamon, Tori, Boucher, Helen W., Geres, Holly, He, Yijie, Mehigan, Maureen, Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Fowler, Vance G. , Patel, Robin , Evans, Scott R , Cross, Heather R, Evans, Scott , Group, for the Antibacterial Resistance Leadership, Lodise, Thomas P. , Schuler, Carl, Holland, Thomas L , Turner, Nicholas , Wilson, Holly, van Duin, David , Wang, Minggui, Evans, Beth, Hopkins, Deborah, Bonomo, Robert A. , Li, Yixuan , Tamma, Pranita D. , Hamasaki, Toshimitsu , Cunningham, Scott A. , Dodd, Andrew, Tsalik, Ephraim L. , Tillekeratne, L. Gayani , King, Heather, Kinamon, Tori, Howard‐Anderson, Jessica , Nayak, Seema , Samuel, Tamika

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S279-S287

10.1093/cid/ciad475 | PMID 37843121 Get It

AbstractIn this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group
Satlin, Michael J. , Tyne, Daria Van , Rouphael, Nadine , Fowler, Vance G. , Hamasaki, Toshimitsu , Patel, Robin , Komarow, Lauren , Baum, Keri, Souli, Maria , Schwager, Nyssa, Doi, Yohei , Group, for the Antibacterial Resistance Leadership, Schooley, Robert T., Evans, Beth , Hopkins, D. E., Cathcart, F, Mocka, Elizabeth, Schuler, Carl, Sund, Zoë, Zaharoff, Smitha, Wickward, Cathy, Estes, Leslie, Mau, Donald, Booth, Grant, Abbenante, Erin, Bhojani, Minal, Zahir, Hirra, Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Li, Yixuan , Zeng, Lijuan , Zhang, Shanshan , Greenwood‐Quaintance, Kerryl E. , Malan, Suzannah Schmidt, Parmar, Krupa , Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Doi, Yohei , Patel, Robin , Van Tyne, Daria , Evans, Scott R , van Duin, David , Tamma, Pranita D. , Lodise, Thomas P. , Rodvold, Keith A. , Evans, Scott , Fowler, Vance G. , Bonomo, Robert A. , Group, for the Antibacterial Resistance Leadership, Wang, Minggui, Wenzler, Eric , Evans, Beth, Hopkins, Deborah, Cathcart, Felecia, Schuler, Carl, Cunningham, Scott A. , Samuel, Tamika, Nayak, Seema

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S305-S313

10.1093/cid/ciad547 | PMID 37843118 Get It

Abstract Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies to define the clinical and molecular global epidemiology of carbapenem-resistant and ceftriaxone-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii, with the goal of optimizing the design and execution of interventional studies. One ongoing ARLG study aims to better understand the impact of fluoroquinolone-resistant gram-negative gut bacteria in neutropenic patients, which threatens to undermine the effectiveness of fluoroquinolone prophylaxis in these vulnerable patients. The ARLG has conducted pharmacokinetic studies to inform the optimal dosing of antibiotics that are important in the treatment of drug-resistant gram-negative bacteria, including oral fosfomycin, intravenous minocycline, and a combination of intravenous ceftazidime-avibactam and aztreonam. In addition, randomized clinical trials have assessed the safety and efficacy of step-down oral fosfomycin for complicated urinary tract infections and single-dose intravenous phage therapy for adult patients with cystic fibrosis who are chronically colonized with P. aeruginosa in their respiratory tract. Thus, the focus of investigation in the ARLG has evolved from improving understanding of drug-resistant gram-negative bacterial infections to positively affecting clinical care for affected patients through a combination of interventional pharmacokinetic and clinical studies, a focus that will be maintained moving forward.
Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group
Hanson, Kimberly E. , Banerjee, Ritu , Doernberg, Sarah B. , Komarow, Lauren , Satlin, Michael J. , Schwager, Nyssa, Simner, Patricia J. , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Abbenante, Erin, Baum, Keri, Souli, Maria , Mocka, Elizabeth, Hopkins, D. E., Giri, Abhigya, Zeng, Lijuan , Greenwood‐Quaintance, Kerryl E. , Booth, Grant, Waller, Jason, Raza, Praneeta , Sund, Zoë, Wickward, Cathy, Dai, Weixiao , Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Patel, Robin , Evans, Scott R , Hanson, Kimberly , Evans, Scott , Tillekeratne, L. Gayani , Group, for the Antibacterial Resistance Leadership, Tsalik, Ephraim L. , Hopkins, Deborah, Dodd, Andrew, Li, Yixuan , Hamasaki, Toshimitsu , Samuel, Tamika

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S314-S320

10.1093/cid/ciad541 | PMID 37843119 Get It

Abstract The advancement of infectious disease diagnostics, along with studies devoted to infections caused by gram-negative and gram-positive bacteria, is a top scientific priority of the Antibacterial Resistance Leadership Group (ARLG). Diagnostic tests for infectious diseases are rapidly evolving and improving. However, the availability of rapid tests designed to determine antibacterial resistance or susceptibility directly in clinical specimens remains limited, especially for gram-negative organisms. Additionally, the clinical impact of many new tests, including an understanding of how best to use them to inform optimal antibiotic prescribing, remains to be defined. This review summarizes the recent work of the ARLG toward addressing these unmet needs in the diagnostics field and describes future directions for clinical research aimed at curbing the threat of antibiotic-resistant bacterial infections.
Management of Scaphotrapeziotrapezoid Osteoarthritis
Alder, Kareme D. , Feroe, Aliya G. , Karim, Kristin E.

JBJS Reviews | October 16, 2023 | Volume: 11 | Issue: 10 | Pages: No page available

10.2106/jbjs.rvw.23.00093 | PMID 38096476 Get It

» The scaphotrapeziotrapezoid (STT) joint is a common location of degenerative osteoarthritis (OA) in the wrist. » STT OA may occur in isolation or with concomitant thumb carpometacarpal joint (CMCJ) OA or scapholunate advanced collapse (SLAC) and other wrist OA patterns. » Nonoperative management strategies include activity modification, bracing, anti-inflammatory medications, occupational therapy, and injections. » Surgical treatment may be determined by whether the STT OA occurs in isolation or with concomitant thumb CMCJ or SLAC OA and includes STT arthrodesis, distal scaphoid excision with or without interposition or implant arthroplasty, trapeziectomy with proximal trapezoid excision, four-corner fusion in combination with scaphoid/radial column excision, and proximal row carpectomy.
Safety and Efficacy of Flow Diverters for Treatment of Unruptured Anterior Communicating Artery Aneurysms: Retrospective Multicenter Study
Benalia, Victor H. C. , Saatçi, Işıl , Cekirge, H Saruhan , Dabus, Guilherme , Brinjikji, Waleed , Nishi, Hidehisa , Siddiqui, Adnan H. , Aghaebrahim, Amin, Sauvageau, Eric , Saatci, Isil , Çekirge, Saruhan , Dabus, Guilherme C. , Nishi, Hidehisa , Monteiro, Andre , Aghaebrahim, Amin , Hanel, Ricardo A , Siddiqui, Adnan H , Cortez, Gustavo M , Mounayer, Charbel , Koçer, Naci , Işlak, Civan , Baltacıoğlu, Feyyaz , Mendes Pereira, Vitor , Lopes, Demetrius K. , Hanel, Ricardó A.

Journal of NeuroInterventional Surgery | October 16, 2023 | Volume: 15 | Issue: 12 | Pages: 1181-1186

10.1136/jnis-2023-020673 | PMID 37845019 Get It

Background The anterior communicating artery (AComm) region is the most common site of intracranial aneurysms, with increased rupture risk compared with other locations. Overall, flow diverters present as a safe and efficacious treatment for intracranial aneurysms, but there is paucity of data for their use in the treatment of unruptured AComm aneurysms. We present the largest multicentric analysis evaluating the outcomes of flow diverters in AComm aneurysm treatment. Methods Databases from 10 centers were retrospectively reviewed for unruptured AComm aneurysms treated with flow diverters. Demographics, clinical presentation, radiographic characteristics, procedural complications, and outcomes were assessed. Results A total of 144 patients harboring 147 AComm aneurysms were treated between January 2012 and December 2021. Seventy-four were women (51.4%) and median age was 60 (IQR 50–67) years. All were unruptured AComm aneurysms. Half of the cohort had similar anterior cerebral artery sizes (51.4%). The most common morphology was saccular (94.6%), with a branch involvement in 32.7% of cases. Median vessel diameter was 2.4 mm, and the Pipeline Flex was the most prevalent device (32.7%). Median follow-up time was 17 months, with complete occlusion in 86.4% at the last follow-up. Functional independence (modified Rankin Scale score 0–2) was reported in 95.1%. Intraprocedural complications occurred in 5.6%, and postoperative complications were noted in 9.7% of cases. Combined major complication and mortality rate was 2.1%. Conclusions Our study suggests that flow diverters are a useful treatment for AComm aneurysms. Mid-term results indicated favorable aneurysm occlusion with a good safety profile. Additional prospective studies with longer follow-up periods and independent adjudication are warranted to better assess these results.
Bilateral Laser Interstitial Thermal Therapy for Butterfly Gliomas Compared With Needle Biopsy: A Preliminary Survival Study
Daggubati, Lekhaj , Merenzon, Martín A. , Bhatia, Shovan , Berry, Katherine , Chandar, Jay , Komotar, Ricardo J., Daggubati, Lekhaj C , Ramos‐Fresnedo, Andres , Morell, Alexis Andres , Shah, Ashish Harish , Ivan, Michael E

Operative Neurosurgery | October 16, 2023 | Volume: 25 | Issue: 5 | Pages: 435-440

10.1227/ons.0000000000000850 | PMID 37846139 Get It

BACKGROUND AND OBJECTIVES: Bilateral/butterfly glioblastoma (bGBM) has a poor prognosis. Resection of these tumors is limited due to severe comorbidities that arise from surgical procedures. Laser interstitial thermal therapy (LITT) offers a minimally invasive cytoreductive therapy for deep-seated tumors such as bGBM. The objective of this study was to evaluate the safety of bilateral LITT in patients with bGBM. METHODS: Medical records of all consecutive patients diagnosed with bGBM by a single surgeon at a single institution from January 2014 to August 2022 were reviewed. Clinical, safety, and radiographic volumetric data were obtained. In addition, an exploratory analysis of survival was performed. RESULTS: A total of 25 patients were included; 14 underwent biopsy only, and 11 underwent biopsy + LITT (7 underwent bilateral and 4 underwent unilateral LITT). No (0%) intraoperative or postoperative complications were recorded in the treatment group. Tumor volume negatively correlated with extent of treatment (r 2 = 0.44, P = .027). The median progression-free survival was 2.8 months in the biopsy-only group and 5.5 months in the biopsy + LITT group ( P = .026). The median overall survival was 4.3 months in the biopsy-only group and 10.3 months in the biopsy + LITT group ( P = .035). CONCLUSION: Bilateral LITT for bGBM can be safely performed and shows early improvement of the progression-free survival and long-term survival outcomes of these patients.
Targeted Therapies in Advanced Cholangiocarcinoma
Storandt, Michael H. , Kurniali, Peter C., Jin, Zhaohui , Achilonu, Conrad Chibunna , Jin, Zhaohui , Achilonu, Conrad C , Mahipal, Amit

Life | October 16, 2023 | Volume: 13 | Issue: 10 | Pages: 2066

10.3390/life13102066 | PMID 37895447 Get It

Primary tumor resection and liver transplantation are the only curative treatment options for the management of cholangiocarcinoma (CCA). However, for patients with advanced or metastatic disease, palliative systemic therapy remains the only treatment option. The development of targeted therapeutics has begun to shift the treatment paradigm in CCA. Targets of interest in CCA include mutated isocitrate dehydrogenase-1 (mIDH-1), human epidermal growth factor receptor 2 (HER2) overexpression/amplification, and fibroblast growth factor receptor 2 (FGFR2) fusion, in addition to less frequently observed targets such as BRAF V600E, deficient mismatch repair/high microsatellite instability (dMMR/MSI-H), and high tumor mutation burden (TMB-H). These targets are observed in varying frequency among patients with intrahepatic CCA and extrahepatic CCA. Multiple novel therapies have been developed to exploit each of these targets, with some having received United States Food and Drug Administration approval for use in the second-line setting. In the current review, we discuss targets of interest in CCA and summarize current evidence evaluating available therapies directed at these targets.
In Reply: Letter: Commentary: Common Carotid Artery to Middle Cerebral Artery Bypass With Radial Interposition Graft for Internal Carotid Artery (ICA) Occlusion After Stent-Coil Embolization of Giant ICA Terminus Aneurysm: 2-Dimensional Operative Video
Bouchal, Samantha M. , Patra, Devi Prasad, Bendok, Bernard R. , Zeeshan, Qazi , Patra, Devi P. , Bouchal, Samantha M

Operative Neurosurgery | October 16, 2023 | Volume: 25 | Issue: 5 | Pages: e300-e300

10.1227/ons.0000000000000892 | PMID 37846144 Get It

ATP functions as a primary alarmin in allergen-induced type 2 immunity
O’Grady, Scott M. , Kita, Hirohito , Kita, H

American Journal of Physiology-Cell Physiology | October 16, 2023 | Volume: 325 | Issue: 5 | Pages: C1369-C1386

10.1152/ajpcell.00370.2023 | PMID 37842751 Get It

Environmental allergens that interact with the airway epithelium can activate cellular stress pathways that lead to the release of danger signals known as alarmins. The mechanisms of alarmin release are distinct from damage-associated molecular patterns (DAMPs), which typically escape from cells after loss of plasma membrane integrity. Oxidative stress represents a form of allergen-induced cellular stress that stimulates oxidant-sensing mechanisms coupled to pathways, which facilitate alarmin mobilization and efflux across the plasma membrane. In this review, we highlight examples of alarmin release and discuss their roles in the initiation of type 2 immunity and allergic airway inflammation. In addition, we discuss the concept of alarmin amplification, where “primary” alarmins, which are directly released in response to a specific cellular stress, stimulate additional signaling pathways that lead to secretion of “secondary” alarmins that include proinflammatory cytokines, such as IL-33, as well as genomic and mitochondrial DNA that coordinate or amplify type 2 immunity. Accordingly, allergen-evoked cellular stress can elicit a hierarchy of alarmin signaling responses from the airway epithelium that trigger local innate immune reactions, impact adaptive immunity, and exacerbate diseases including asthma and other chronic inflammatory conditions that affect airway function.
Lower muscle protein synthesis in humans with obesity concurrent with lower expression of muscle IGF1 splice variants
Freitas, Eduardo D. S. , Kras, Katon A., Roust, Lori R., Filippis, Elena A. De, Kimball, Scot R. , Katsanos, Christos S. , De Filippis, Elena A, Katsanos, Christos S , Buras, Matthew

Obesity | October 16, 2023 | Volume: 31 | Issue: 11 | Pages: 2689-2698

10.1002/oby.23896 | PMID 37840435 Get It

AbstractObjectiveThis study tested the hypothesis that expression of insulin‐like growth factor 1 (IGF‐1) protein and mRNA splice variants is lower in skeletal muscle of humans with obesity who have a lower mixed‐muscle protein fractional synthesis rate (MMP‐FSR) when compared with individuals without obesity.MethodsThe study included nine participants with obesity (OB, mean [SD], BMI = 35 [3] kg/m2, MMP‐FSR = 0.06%/h [0.02%/h]) and nine participants without obesity (W‐OB, BMI = 24 [3] kg/m2, MMP‐FSR = 0.08%/h [0.02%/h]; for both BMI and MMP‐FSR p < 0.05). MMP‐FSR and mitochondrial protein FSR were measured following an overnight fast.ResultsAlong with lower MMP‐FSR, OB participants displayed lower mitochondrial protein FSR (p = 0.03) compared with W‐OB participants. Expression of IGF‐1 (p = 0.04) and IGF‐1 receptor (p < 0.01) proteins was lower in muscle of OB participants. In addition, OB participants had lower (p < 0.05) mRNA expression of IGF1 variants Eb and Ec. This study demonstrates that lower protein synthesis in muscle of humans with obesity occurs concurrently with lower expression of muscle IGF‐1 and IGF‐1 receptor proteins, as well as lower mRNA expression of the IGF1 splice variants.ConclusionsThese findings indicate that lower protein synthesis observed in muscle of humans with obesity may result from diminished muscle IGF1 gene expression.